Hyperpolarized 129Xe MRI for Imaging Pulmonary Function in Lung Disease
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new method of using MRI with a special gas, 129Xe, to better visualize lung function. Researchers aim to understand lung diseases like fibrosis, emphysema, and pulmonary hypertension by observing how the gas moves through the lungs. Potential participants include individuals diagnosed with lung issues who have not experienced a flare-up in the last 30 days, as well as healthy individuals with no smoking history in the past five years. As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group, offering participants a chance to contribute to important advancements in understanding lung diseases.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It might be best to discuss this with the trial coordinators or your doctor.
What prior data suggests that this MRI technique is safe for imaging pulmonary function?
Research has shown that hyperpolarized 129Xe MRI, which uses a special type of xenon gas for imaging, holds promise for assessing lung function. Studies have demonstrated that this technique provides clear images of lung function. Importantly, previous studies of hyperpolarized 129Xe MRI reported no negative side effects, although these studies did not specifically focus on testing safety and comfort.
Xenon gas is already considered safe in other medical uses, suggesting that this MRI method should be well-tolerated. In the current trial phase, researchers are still gathering detailed safety information. This phase usually indicates some evidence of safety exists, but more data is needed to confirm it.12345Why are researchers excited about this trial?
Hyperpolarized 129Xe MRI is unique because it uses a special form of xenon gas to create highly detailed images of lung function, unlike traditional imaging methods like CT scans or standard MRIs that primarily show structure. Researchers are excited because this technique can reveal how well different parts of the lungs are working, providing insights into lung diseases that current methods can't easily offer. This could lead to better diagnosis and monitoring of lung diseases, potentially improving personalized treatment plans for patients.
What evidence suggests that Hyperpolarized 129Xe MRI is effective for imaging pulmonary function in lung disease?
Research has shown that hyperpolarized xenon-129 MRI (129Xe MRI) offers a promising way to evaluate lung function. This technique uses a special gas to produce detailed images of air movement and gas exchange in the lungs. Studies have found that 129Xe MRI accurately detects and assesses lung diseases such as fibrosis and emphysema. This noninvasive method, which does not involve surgery or entering the body, provides a clear picture of lung health. Early results suggest it can be as effective as other methods, like 133Xe scintigraphy, while offering more detailed information on lung function.24678
Who Is on the Research Team?
Joseph Mammarappallil, M.D.
Principal Investigator
Duke University
Are You a Good Fit for This Trial?
This trial is for adults with stable lung function who haven't had a worsening of their condition in the last month. Smokers can join if they've smoked 5 or fewer pack-years. There's also a group for healthy people without lung issues and who haven't smoked in 5 years.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Imaging
Participants undergo HP 129Xe MRI to assess pulmonary function, including ventilation distribution, alveolar microstructure, and gas exchange.
Follow-up
Participants are monitored for safety and effectiveness after imaging, with a focus on recording any adverse events.
What Are the Treatments Tested in This Trial?
Interventions
- Hyperpolarized 129Xe MRI
Find a Clinic Near You
Who Is Running the Clinical Trial?
Bastiaan Driehuys
Lead Sponsor